{"title":"Proteomic technologies for profiling cell-membrane/secretome interactions in brain metastatic cancer progression.","authors":"Iulia M Lazar","doi":"10.1080/14789450.2025.2536061","DOIUrl":"https://doi.org/10.1080/14789450.2025.2536061","url":null,"abstract":"<p><strong>Introduction: </strong>. The ability of cancer cells to disseminate from the primary tumor and form metastatic lesions frequently leads to fatal outcomes. Recently, however, it has been recognized that this process is driven by complex interactions between the cancer and the neighboring cells, and, overall, made possible by a supportive tumor microenvironment. The emergence of high-throughput technologies is expected to bring much needed clarity to unraveling the players and intricate communication pathways that promote metastatic progression.</p><p><strong>Areas covered: </strong>In this report, the impact of mass spectrometry and proteomic technologies on deciphering the cross-talk between cancer and tumor microenvironment cells is discussed. Focus is placed on the role of cell-membrane and secretome proteins as the main enablers of this cross-talk, and on the challenges presented by metastatic tumors that evolve in the brain. Future prospects are assessed in the context of recent biology, technology, and data analysis breakthroughs.</p><p><strong>Expert opinion: </strong>Advancements in high-throughput proteomic technologies, complemented by the exciting potential of new disease model systems and data processing abilities of artificial intelligence, are expected to bring groundbreaking progress in deciphering the fundamental biological mechanisms that support cancer behavior and metastatic development, revealing novel therapeutic targets, and guiding innovative intervention approaches.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bent Honoré, Lasse Jørgensen Cehofski, Steffen Heegaard, Ivan Brandslund, Henrik Vorum, Carina Slidsborg
{"title":"Proteomic blood-biomarkers for personalized risk stratification of diabetic retinopathy patients.","authors":"Bent Honoré, Lasse Jørgensen Cehofski, Steffen Heegaard, Ivan Brandslund, Henrik Vorum, Carina Slidsborg","doi":"10.1080/14789450.2025.2534399","DOIUrl":"https://doi.org/10.1080/14789450.2025.2534399","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes mellitus (DM) is a challenging chronic disease worldwide. The incidence is expected to rise dramatically by 2030 due to smoking, obesity and aging population. This increases public health burden in coming years. Diabetic retinopathy (DR) is a common microvascular complication and a leading cause of blindness among working-age individuals. Understanding the proteomic mechanisms driving disease progression and visual loss is of paramount importance when laying novel strategies for managing patients in clinical practice.</p><p><strong>Areas covered: </strong>We summarize proteomic studies addressing molecular biomarkers in human blood for DR. We discuss methodological advantages and challenges. Proteomic technology advancement has reached a level where even low-abundance proteins related to disease can be detected in blood. The pooled results of these studies suggested that the biomarkers are specific to disease stage and hold promise for personalized risk stratification in DR.</p><p><strong>Expert opinion: </strong>With development of advanced mass spectrometry technology for investigation of blood-biomarkers, this research area is expected to advance in near future. Similarly, it is expected that novel blood-based biomarkers for DR will be validated in international studies and implemented in clinical practice. Therefore, future perspectives hold promises of personalized risk profiling for diagnosis, progression and optimal choice of treatment.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hyeyoon Kim, David Ross Hall, Lorenz Nierves, Tai-Tu Lin, Reta Birhanu Kitata, Tujin Shi, Tao Liu
{"title":"The evolution of analytical techniques for multiplex analysis of protein biomarkers.","authors":"Hyeyoon Kim, David Ross Hall, Lorenz Nierves, Tai-Tu Lin, Reta Birhanu Kitata, Tujin Shi, Tao Liu","doi":"10.1080/14789450.2025.2529185","DOIUrl":"10.1080/14789450.2025.2529185","url":null,"abstract":"<p><strong>Introduction: </strong>The landscape of biomarker development has evolved with advanced analytical technologies, particularly affinity- and mass spectrometry-based techniques. These advancements have deepened our understanding of disease mechanisms, enabling the development of precise diagnostic tools and personalized medicine. Protein biomarkers, which play pivotal roles in biological processes, have become invaluable in diagnosing and monitoring diseases, aided by their presence in various biological samples and the availability of established detection methods.</p><p><strong>Areas covered: </strong>This review covers the role of protein biomarkers in clinical practice, the development and dimensionality of protein biomarkers, advancements in detection technologies, a comparison of these technologies, and future directions in biomarker discovery and disease mechanism elucidation.</p><p><strong>Expert opinion: </strong>Advances in biomarker technologies have the potential to transform diagnostics and personalized treatment but face challenges such as high costs and technical complexity. Enhancing reproducibility and integrating multi-omics approaches may offer better insights. The field should evolve toward high-throughput, automated methods, continuously adapting research, and clinical practices.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":"1-18"},"PeriodicalIF":3.8,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sonia Spinelli, Andrea Garbarino, Marco Pavanello, Giovanni Candiano, Isabella Panfoli, Maurizio Bruschi
{"title":"Extracellular vesicle proteomics in brain solid tumors: future strategy for personalized medicine.","authors":"Sonia Spinelli, Andrea Garbarino, Marco Pavanello, Giovanni Candiano, Isabella Panfoli, Maurizio Bruschi","doi":"10.1080/14789450.2025.2514841","DOIUrl":"10.1080/14789450.2025.2514841","url":null,"abstract":"<p><strong>Introduction: </strong>Brain solid tumors are a leading cause of cancer-related mortality at all ages. The updated 2021WHO Central Nervous System tumor classification is based on genomic diagnostics. Nonetheless, extracellular vesicles (EVs) proteomics is a platform for protein biomarker discovery in brain tumor patient management. Tumor metabolic reprogramming, also through epigenetic mechanisms, is central to cancer. EVs transfer proteins and nucleic acids that relay the metabolic and redox state of the parent cells.</p><p><strong>Areas covered: </strong>This review addresses the biomarker discovery and translation focusing on recent (from 2022 to 2024 PubMed) proteomic studies of EVs in brain tumor patients, selected for their focus on metabolic aspects. The most treatable adult brain tumor is isocitrate dehydrogenase-mutated glioma. Minimally invasive collection of EVs from cerebrospinal fluid or prospectively blood allows proteomic and metabolic analysis of the parent tumor cells.</p><p><strong>Expert opinion: </strong>The CSF EVs express key CNS tumor biomarkers and therapy targets undetectable in whole CSF and relay the brain tumor metabolic adaptations. Metabolic dependencies can represent potential therapy targets. The clinical implications of biomarker EV proteomic discovery represent a promising platform for diagnostic and prognostic purposes in brain solid tumors, a leading cause of cancer-related mortality at all ages.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":"217-224"},"PeriodicalIF":3.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emil Johansson, Maria Jesus Iglesias, Jacob Odeberg, Fredrik Edfors
{"title":"Shaping the future of precision medicine: plasma proteomics to uncover insights in thrombosis.","authors":"Emil Johansson, Maria Jesus Iglesias, Jacob Odeberg, Fredrik Edfors","doi":"10.1080/14789450.2025.2517146","DOIUrl":"10.1080/14789450.2025.2517146","url":null,"abstract":"<p><strong>Introduction: </strong>Advances in various proteomics technologies, especially high-throughput and reproducibility, have enabled the systematic exploration of the circulating thrombosis proteome. This includes dissecting biological systems and pathways imperative to thrombosis, such as platelet activation, coagulation cascade, complement system, and endothelial cells. These insights strengthen our understanding of the cause and effect of thrombosis and improve precision medicine by identifying better biomarkers and biomarker panels, which may aid clinicians in decision-making in venous thromboembolism (VTE) and other thrombotic patients. This progress has the potential to reduce thrombosis-related morbidity and mortality, ultimately improving patient quality of life.</p><p><strong>Areas covered: </strong>This review highlights recent advances and applications of mass spectrometry and affinity-based proteomics in thrombosis over the past three years (2022-2024), focusing on the thrombotic proteome signature related to VTE.</p><p><strong>Expert opinion: </strong>Plasma proteomics, predominantly driven by mass spectrometry and affinity-based proteomics, has shown promise in identifying novel disease biomarkers and pathways. With the recent advances in the field, proteomics holds the potential to revolutionize precision medicine. As thrombosis is an intravascular disease, analysis of the blood proteome can capture environmental, genetic, and epigenetic contributors to risk variation in thrombosis, revealing novel protein biomarkers for diagnosis and risk prediction and new biological pathways.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":"237-254"},"PeriodicalIF":3.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Silvia Romero-Murillo, Seojin Lee, Joaquín Fernández-Irigoyen, Ivan Martinez-Valbuena, Enrique Santamaría
{"title":"The potential of proteomics for in-depth molecular investigations of progressive supranuclear palsy.","authors":"Silvia Romero-Murillo, Seojin Lee, Joaquín Fernández-Irigoyen, Ivan Martinez-Valbuena, Enrique Santamaría","doi":"10.1080/14789450.2025.2519466","DOIUrl":"10.1080/14789450.2025.2519466","url":null,"abstract":"<p><strong>Introduction: </strong>Progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder. The lack of comprehension about the pathogenesis of the disease, its heterogeneity, and the complex clinical evaluation in early stages, limit the development of effective treatments for PSP patients and highlight the need of further research on the field.</p><p><strong>Areas covered: </strong>In this work, we review the current knowledge of the physio- and neuropathology of PSP, its clinical features, diagnosis markers, and treatment options. We also compare the proteomic-based studies done to date in brain tissues as well as in cerebrospinal fluid and other non-cerebral samples, briefly describing the proteomic approach used and the biological findings obtained in each study.</p><p><strong>Expert opinion: </strong>PSP is a complex neurodegenerative disorder marked by tau aggregation, glial dysfunction, and neuroinflammation. Although advances in neuroimaging and biofluid biomarkers have improved PSP diagnostic accuracy, no disease-modifying therapies are currently available. Promising avenues such as tau PET tracers, seed amplification assays, and advanced proteomic-based approaches are enhancing our ability to detect disease-specific tau pathology and hold the potential to provide novel biomarkers for earlier and more precise clinical diagnosis and treatment development that could transform the landscape of PSP.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":"225-235"},"PeriodicalIF":3.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immobilized metal ion affinity chromatography: waltz of metal ions and biomacromolecules.","authors":"Rui Yan, Yan-Ming Xu, Andy T Y Lau","doi":"10.1080/14789450.2025.2492764","DOIUrl":"10.1080/14789450.2025.2492764","url":null,"abstract":"<p><strong>Introduction: </strong>Immobilized metal ion affinity chromatography (IMAC) is an effective method developed in the 1980s for the separation and purification of proteins. The system consists of a solid-phase matrix, a linking ligand, and a metal ion. The method is based on the ability of metal ions to bind specifically to certain specific amino acid residues of proteins, thereby selectively enriching and purifying proteins.</p><p><strong>Areas covered: </strong>This review aims to describe current knowledge of fundamental principle of IMAC and summarize the supports, chelating ligands, and metal ions of IMAC. In addition, how IMAC technology is used in proteomics and nucleic acids research are highlighted.</p><p><strong>Expert opinion: </strong>Over the past decades, IMAC has been extensively utilized as a predominant technique for protein enrichment in a variety of biological and medical research, such as disease diagnosis, tumor biomarker identification, protein purification, and nucleic acids research. In the future, IMAC should be integrated with other emerging proteomics technologies to promote the applications of metalloproteomes in disease diagnosis, metallodrug development, and clinical translation.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":"185-198"},"PeriodicalIF":3.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Valerie Prochazkova, Michal Rosulek, Michael Karpisek, Vaclav Matousek, Petr Novak, Zdenek Kukacka
{"title":"Utilization of high-resolution mass spectrometry and data-independent analysis to track the monoclonal antibody spatial stability.","authors":"Valerie Prochazkova, Michal Rosulek, Michael Karpisek, Vaclav Matousek, Petr Novak, Zdenek Kukacka","doi":"10.1080/14789450.2025.2492763","DOIUrl":"10.1080/14789450.2025.2492763","url":null,"abstract":"<p><strong>Objectives: </strong>Chemical cross-linking coupled with mass spectrometry (CXMS) offers the distance constraints critical for building the structural model of protein and protein complexes and understanding dynamics of biological systems. Originally developed for protein structural models, CXMS has evolved into method for studying protein complex formation, ligand-induced conformational changes, and quantitative structural analysis using isotopically labeled cross-linkers.</p><p><strong>Methods: </strong>In this study we tested the potential of isotopically labeled MS-cleavable cross-linker to track the stability of the therapeutic monoclonal antibodies.</p><p><strong>Results: </strong>A novel isotopically labeled MS-cleavable cross-linker was synthesized, and its reactivity was successfully tested on peptide and protein standards. Further, the novel cross-linker was utilized to test the stability of selected therapeutical monoclonal antibodies, bevacizumab and trastuzumab, adopting the data-independent acquisition.</p><p><strong>Conclusion: </strong>This study reports the advantages of using combination of <sup>13</sup>C isotopically labeled MS-cleavable cross-linkers and data-independent mass spectrometry analysis for the automated identification of cross-linked products and thus monitoring the structural rearrangement of protein structure.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":"199-207"},"PeriodicalIF":3.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kari Arnarson, Kristrun Y Holm, Valdis Gunnarsdottir Thormar, Finnur F Eiríksson, Yassene Mohammed, Christoph H Borchers, Sigridur K Bodvarsdottir, Margret Thorsteinsdottir
{"title":"Optimization of bottom-up proteomic sample preparation by design of experiments for absolute quantification of 257 proteins in human plasma using UPLC-MRM-MS.","authors":"Kari Arnarson, Kristrun Y Holm, Valdis Gunnarsdottir Thormar, Finnur F Eiríksson, Yassene Mohammed, Christoph H Borchers, Sigridur K Bodvarsdottir, Margret Thorsteinsdottir","doi":"10.1080/14789450.2025.2504994","DOIUrl":"10.1080/14789450.2025.2504994","url":null,"abstract":"<p><strong>Introduction: </strong>Targeted protein absolute quantification using mass spectrometry holds promise for identifying biomarkers for diagnosis, prognosis, and personalized medicine. However, complex and time-consuming workflows, particularly during sample preparation, present significant bottlenecks. Addressing these challenges is critical for the applicability of absolute quantification of proteins in clinical research settings.</p><p><strong>Areas covered: </strong>We explore optimization strategies for protein digestion in bottom-up proteomics sample preparation. Design of experiments (DoE), a statistical approach for systematically evaluating multiple experimental factors, was used for simultaneous optimization of digestion time, temperature, enzyme-to-protein substrate ratio, and denaturing agent. Furthermore, the lower limit of quantification (LLOQ) for our platform was improved by using the Waters Xevo TQ-XS UPLC-MRM-MS. The integration of automated sample preparation into the workflow enabled reproducible absolute quantification of 257 proteins in human plasma.</p><p><strong>Expert opinion: </strong>We successfully reduced protein digestion time from 18 hours (overnight) to 4 hours while maintaining relative digestion efficiency. We improved the sensitivity of the assay via the optimized workflow and were able to quantify proteins that previously fell below the LLOQ. These advancements, combined with automation, provide a practical, efficient, and reproducible workflow suitable for clinical research.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":"209-216"},"PeriodicalIF":3.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zuzana Kalaninova, Josef Dvorak, Jiri Dresler, Michael Volny, Petr Novak, Petr Pompach
{"title":"Novel activity assay for botulotoxin A1 detection using functionalized chips and matrix-assisted laser desorption/ionization mass spectrometry.","authors":"Zuzana Kalaninova, Josef Dvorak, Jiri Dresler, Michael Volny, Petr Novak, Petr Pompach","doi":"10.1080/14789450.2025.2482933","DOIUrl":"10.1080/14789450.2025.2482933","url":null,"abstract":"<p><strong>Background: </strong>Botulinum neurotoxins (BoNTs) are a group of neurotoxins produced by Clostridium bacteria. Their effect on neuro-muscular connections through cleaving proteins of the SNARE complex results in blocking acetylcholine signal transduction. The FDA-approved mouse bioassay, which involves exposing live mice to potentially contaminated food, is the most widely used method. However, this assay is costly, time-consuming, and raises ethical concerns. Therefore, there is a need for alternative assays that can enzymatically measure the activity of BoNTs.</p><p><strong>Research design and methods: </strong>We present an approach that combines the EndoPep-MS assay with protein affinity chips fabricated using ion soft-landing technology. Toxic activity is indirectly assessed by monitoring the N- and C-terminal fragments of the substrate peptide. This new method employs a protein array with affinity molecules targeting either the BoNT/A1 or the substrate peptide. Both variants enable <i>in-situ</i> reaction and detection of substrate peptides via MALDI-ToF MS on the protein chip.</p><p><strong>Results: </strong>This method demonstrated successful detection of active BoNT/A1 in both buffer and complex matrices, achieving a detection limit of 0.5 ng/mL.</p><p><strong>Conclusions: </strong>This study reports the <i>in-situ</i> detection of botulotoxin A1 using functionalized MALDI chips. The advantages of the MALDI chip technology include speed, robustness, cost-effectiveness, and possible automatization.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":"177-184"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}